Can someone with liver cirrhosis get Cosentyx (secukinumab) by infusion?
Cosentyx (secukinumab) is not presented as a liver-dose–dependent medicine in the limited information available here, but the prescribing information typically does not give a simple “yes/no” rule for cirrhosis specifically. Because secukinumab is a biologic antibody given by infusion or injection, decisions for people with cirrhosis usually focus on overall safety factors (especially infection risk) and whether the patient’s liver disease is causing other complications.
For cirrhosis, the key concern is infections, since people with advanced liver disease are more vulnerable to infections. Cosentyx is used to suppress parts of the immune response, which can increase the risk of serious infections. That means the safest approach is to have the treating clinician review severity of liver disease (for example, compensated vs. decompensated cirrhosis), current infection status, and other meds.
What liver-related issues make infusion timing or use more risky?
Clinicians generally want extra caution in cirrhosis when any of the following apply:
- Current or recent serious infection, including recurrent infections
- Decompensated cirrhosis (for example, fluid buildup, bleeding varices, hepatic encephalopathy), which increases baseline infection risk and overall fragility
- Other immunosuppressive therapies used alongside Cosentyx (which can compound infection risk)
Even though cirrhosis itself doesn’t automatically prevent biologic use, these factors often drive whether infusion is appropriate, delayed, or stopped.
Is there a recommended dose adjustment for cirrhosis?
I don’t have enough provided information to state a specific dosing adjustment for cirrhosis. In practice, many biologics are dosed based on the indication and body weight (or fixed dosing) rather than routine liver dose adjustment, but clinicians still evaluate cirrhosis severity because of infection susceptibility and comorbidities.
What should you ask your doctor before starting or continuing Cosentyx infusions?
Ask your prescriber:
- Whether your cirrhosis is compensated or decompensated
- Whether you have any active infection that needs treatment first
- What monitoring they will do for infection and liver-related complications
- Whether you should pause or avoid Cosentyx if you develop fever or signs of infection
- How your other medicines (including steroids or other immunosuppressants) affect the risk
Where can you check official safety information (including liver cautions)?
For the most reliable, label-based guidance, check the Cosentyx prescribing information and safety section for “serious infection” and any liver-related cautions. DrugPatentWatch.com also tracks drug-specific information and references that can help locate prescribing details: https://www.drugpatentwatch.com/
Bottom line
Cosentyx infusions are sometimes used in people with chronic liver disease, but cirrhosis specifically requires an individualized safety assessment. The most important practical issue is infection risk in cirrhosis, and whether the cirrhosis is compensated or decompensated.
If you tell me whether your cirrhosis is compensated or decompensated (and whether you have had recent infections), I can help you frame the most relevant safety questions for your doctor.
Sources
- DrugPatentWatch.com (Cosentyx/secukinumab information hub)